# BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

> **NCT02246439** · PHASE3 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 330 (actual)

## Conditions studied

- Gastroenteritis
- Gastritis

## Interventions

- **DRUG:** RHB-102
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT02246439
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-08
- **Primary completion:** 2017-02-13
- **Final completion:** 2017-02-16
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2019-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246439, "BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02246439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*